Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A. Frerichs, Niels W.C.J. van de Donk, Christie P.M. Verkleij et al.|Blood Advances|2023Cited by 85
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)Gustaaf W. van Imhoff, Anton Hagenbeek, Kirit M. Ardeshna et al.|Blood|2014Cited by 25